178 related articles for article (PubMed ID: 15702622)
1. Early target organ damage and its reversibility: the heart.
Rosei EA; Muiesan ML
Clin Exp Hypertens; 2004; 26(7-8):673-87. PubMed ID: 15702622
[TBL] [Abstract][Full Text] [Related]
2. Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment.
Agabiti-Rosei E
Blood Press Suppl; 1997; 2():13-5. PubMed ID: 9495620
[TBL] [Abstract][Full Text] [Related]
3. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
Bang CN; Devereux RB; Okin PM
J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
[TBL] [Abstract][Full Text] [Related]
4. The importance of left ventricular hypertrophy in human hypertension.
Kahan T
J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
[TBL] [Abstract][Full Text] [Related]
5. [The effect of hypotensive drugs on left ventricular mass and diastolic function].
Spring A; Haczyński J; Jołda-Mydłowska B; Witkowska M
Pol Arch Med Wewn; 1995 Jul; 94(1):47-58. PubMed ID: 8524699
[TBL] [Abstract][Full Text] [Related]
6. Hypertension and Organ Damage in Women.
Muiesan ML; Paini A; Aggiusti C; Bertacchini F; Rosei CA; Salvetti M
High Blood Press Cardiovasc Prev; 2018 Sep; 25(3):245-252. PubMed ID: 29943358
[TBL] [Abstract][Full Text] [Related]
7. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
Agabiti-Rosei E; Muiesan ML
J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
9. The heart in the hypertensive elderly.
Grodzicki T; Messerli FH
J Hum Hypertens; 1998 Sep; 12(9):593-7. PubMed ID: 9783486
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the cardiac effects of antihypertensive agents.
Agabiti-Rosei E
J Cardiovasc Pharmacol; 1994; 23 Suppl 5():S42-8. PubMed ID: 7609505
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of subclinical target organ damage for risk assessment and treatment in the hypertensive patients: left ventricular hypertrophy.
Agabiti-Rosei E; Muiesan ML; Salvetti M
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S104-8. PubMed ID: 16565230
[TBL] [Abstract][Full Text] [Related]
12. Changes in midwall systolic performance and cardiac hypertrophy reduction in hypertensive patients.
Muiesan ML; Salvetti M; Monteduro C; Rizzoni D; Corbellini C; Castellano M; Porteri E; Agabiti-Rosei E
J Hypertens; 2000 Nov; 18(11):1651-6. PubMed ID: 11081779
[TBL] [Abstract][Full Text] [Related]
13. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
Gradman AH; Alfayoumi F
Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048
[TBL] [Abstract][Full Text] [Related]
14. Left Ventricular Hypertrophy in Hypertensive Athletes can be Reduced by Antihypertensive Medication Despite Continuing Intense Aerobic Exercise.
Ketelhut S; Franz IW; Ketelhut RG
High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):385-390. PubMed ID: 30341642
[TBL] [Abstract][Full Text] [Related]
15. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Bang CN; Gerdts E; Aurigemma GP; Boman K; de Simone G; Dahlöf B; Køber L; Wachtell K; Devereux RB
Circ Cardiovasc Imaging; 2014 May; 7(3):422-9. PubMed ID: 24723582
[TBL] [Abstract][Full Text] [Related]
16. Effects of antihypertensive agents on the left ventricle: clinical implications.
Díez J; González A; López B; Ravassa S; Fortuño MA
Am J Cardiovasc Drugs; 2001; 1(4):263-79. PubMed ID: 14728026
[TBL] [Abstract][Full Text] [Related]
17. Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis.
Bayés-Genís A; Guindo J; Viñolas X; Tomás L; Elosua R; Duran I; Bayés de Luna A
Am J Cardiol; 1995 Nov; 76(13):54D-59D. PubMed ID: 7495219
[TBL] [Abstract][Full Text] [Related]
18. Optimal antihypertensive therapy for prevention and treatment of left ventricular hypertrophy.
Liebson PR; Serry RD
Curr Hypertens Rep; 2000 Jun; 2(3):260-70. PubMed ID: 10981159
[TBL] [Abstract][Full Text] [Related]
19. Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy.
Mayet J; Ariff B; Wasan B; Chapman N; Shahi M; Poulter NR; Sever PS; Foale RA; Thom SA
Hypertension; 2000 Nov; 36(5):755-9. PubMed ID: 11082139
[TBL] [Abstract][Full Text] [Related]
20. Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality.
Kaplinsky E
Cardiovasc Drugs Ther; 1994 Aug; 8 Suppl 3():549-56. PubMed ID: 7841088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
